Cargando…

Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults

BACKGROUND: Recurrent seizure risks in HIV-positive people with new-onset seizure are largely unknown, making it challenging to offer optimal recommendations regarding antiepileptic drug (AED) initiation. Existing outcomes data is limited, and risk factor identification requires a diagnostic assessm...

Descripción completa

Detalles Bibliográficos
Autores principales: Elafros, Melissa A., Johnson, Brent A., Siddiqi, Omar K., Okulicz, Jason F., Sikazwe, Izukanji, Bositis, Christopher M., Potchen, Michael J., Koralnik, Igor J., Theodore, William H., Kalungwana, Lisa, Birbeck, Gretchen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284303/
https://www.ncbi.nlm.nih.gov/pubmed/30522451
http://dx.doi.org/10.1186/s12883-018-1205-2
_version_ 1783379312472227840
author Elafros, Melissa A.
Johnson, Brent A.
Siddiqi, Omar K.
Okulicz, Jason F.
Sikazwe, Izukanji
Bositis, Christopher M.
Potchen, Michael J.
Koralnik, Igor J.
Theodore, William H.
Kalungwana, Lisa
Birbeck, Gretchen L.
author_facet Elafros, Melissa A.
Johnson, Brent A.
Siddiqi, Omar K.
Okulicz, Jason F.
Sikazwe, Izukanji
Bositis, Christopher M.
Potchen, Michael J.
Koralnik, Igor J.
Theodore, William H.
Kalungwana, Lisa
Birbeck, Gretchen L.
author_sort Elafros, Melissa A.
collection PubMed
description BACKGROUND: Recurrent seizure risks in HIV-positive people with new-onset seizure are largely unknown, making it challenging to offer optimal recommendations regarding antiepileptic drug (AED) initiation. Existing outcomes data is limited, and risk factor identification requires a diagnostic assessment, which is often unavailable in regions heavily effected by HIV, like sub-Saharan Africa. METHODS: HIV-positive Zambian adults with new-onset seizure were enrolled in a prospective cohort study to determine seizure recurrence and risk factors for recurrence. Seizure etiology was evaluated, and recurrent seizures and medication usage were assessed during clinic visits. Due to unexpectedly high mortality rates, predictors of death were evaluated using proportional hazards with Gray’s test to compare cumulative incidence functions for recurrent seizure across groups adjusting for the competing outcome of death. RESULTS: 95 patients were enrolled (mean age 37 years, 43% female, 83% with Karnofsky > 50) and followed for a mean of 293 days (median 241 (IQR: 29–532)). At presentation, 50 (53%) were in status epilepticus. The majority (91, 85%) had advanced HIV disease and 65 (68%) were not on combined antiretroviral therapy (cART). After extensive workup, seizure etiology remained unknown in 16 (17%). Average time to cART initiation after enrollment was 61 days. During follow up, 37 (39%) died and 23 (24%) had recurrent seizure. Most deaths (25/37, 68%) occurred in the first 60 days post-index seizure. Individuals with advanced HIV were more likely to die (HR: 19.1 [95% CI: 1.1–333.4]) as were those whose seizure etiology remained unknown (HR: 2.2 [95% CI: 1.1–4.4]). Among participants that survived from enrolment to the end of data collection on 10 May 2013 (n = 58), 20 (34%) experienced recurrent seizures. CONCLUSIONS: New-onset seizure among HIV-positive Zambian adults is associated with high mortality despite good functional status prior to presentation. Advanced HIV infection and failure to identify an underlying seizure etiology are associated with greater mortality. Recurrent seizures occur in over a third of survivors within only 2 years of follow-up. This provides evidence to support AED initiation after first seizure in HIV-positive individuals with advanced HIV disease at the time of presentation though the risks of AED-cART interactions remain a concern and warrant further study.
format Online
Article
Text
id pubmed-6284303
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62843032018-12-14 Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults Elafros, Melissa A. Johnson, Brent A. Siddiqi, Omar K. Okulicz, Jason F. Sikazwe, Izukanji Bositis, Christopher M. Potchen, Michael J. Koralnik, Igor J. Theodore, William H. Kalungwana, Lisa Birbeck, Gretchen L. BMC Neurol Research Article BACKGROUND: Recurrent seizure risks in HIV-positive people with new-onset seizure are largely unknown, making it challenging to offer optimal recommendations regarding antiepileptic drug (AED) initiation. Existing outcomes data is limited, and risk factor identification requires a diagnostic assessment, which is often unavailable in regions heavily effected by HIV, like sub-Saharan Africa. METHODS: HIV-positive Zambian adults with new-onset seizure were enrolled in a prospective cohort study to determine seizure recurrence and risk factors for recurrence. Seizure etiology was evaluated, and recurrent seizures and medication usage were assessed during clinic visits. Due to unexpectedly high mortality rates, predictors of death were evaluated using proportional hazards with Gray’s test to compare cumulative incidence functions for recurrent seizure across groups adjusting for the competing outcome of death. RESULTS: 95 patients were enrolled (mean age 37 years, 43% female, 83% with Karnofsky > 50) and followed for a mean of 293 days (median 241 (IQR: 29–532)). At presentation, 50 (53%) were in status epilepticus. The majority (91, 85%) had advanced HIV disease and 65 (68%) were not on combined antiretroviral therapy (cART). After extensive workup, seizure etiology remained unknown in 16 (17%). Average time to cART initiation after enrollment was 61 days. During follow up, 37 (39%) died and 23 (24%) had recurrent seizure. Most deaths (25/37, 68%) occurred in the first 60 days post-index seizure. Individuals with advanced HIV were more likely to die (HR: 19.1 [95% CI: 1.1–333.4]) as were those whose seizure etiology remained unknown (HR: 2.2 [95% CI: 1.1–4.4]). Among participants that survived from enrolment to the end of data collection on 10 May 2013 (n = 58), 20 (34%) experienced recurrent seizures. CONCLUSIONS: New-onset seizure among HIV-positive Zambian adults is associated with high mortality despite good functional status prior to presentation. Advanced HIV infection and failure to identify an underlying seizure etiology are associated with greater mortality. Recurrent seizures occur in over a third of survivors within only 2 years of follow-up. This provides evidence to support AED initiation after first seizure in HIV-positive individuals with advanced HIV disease at the time of presentation though the risks of AED-cART interactions remain a concern and warrant further study. BioMed Central 2018-12-07 /pmc/articles/PMC6284303/ /pubmed/30522451 http://dx.doi.org/10.1186/s12883-018-1205-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Elafros, Melissa A.
Johnson, Brent A.
Siddiqi, Omar K.
Okulicz, Jason F.
Sikazwe, Izukanji
Bositis, Christopher M.
Potchen, Michael J.
Koralnik, Igor J.
Theodore, William H.
Kalungwana, Lisa
Birbeck, Gretchen L.
Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults
title Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults
title_full Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults
title_fullStr Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults
title_full_unstemmed Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults
title_short Mortality & recurrent seizure risk after new-onset seizure in HIV-positive Zambian adults
title_sort mortality & recurrent seizure risk after new-onset seizure in hiv-positive zambian adults
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284303/
https://www.ncbi.nlm.nih.gov/pubmed/30522451
http://dx.doi.org/10.1186/s12883-018-1205-2
work_keys_str_mv AT elafrosmelissaa mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT johnsonbrenta mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT siddiqiomark mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT okuliczjasonf mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT sikazweizukanji mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT bositischristopherm mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT potchenmichaelj mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT koralnikigorj mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT theodorewilliamh mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT kalungwanalisa mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults
AT birbeckgretchenl mortalityrecurrentseizureriskafternewonsetseizureinhivpositivezambianadults